RANDOMIZED CLINICAL-TRIAL OF 2 TREATMENT REGIMENS OF NATURAL SURFACTANT PREPARATIONS IN NEONATAL RESPIRATORY-DISTRESS-SYNDROME

被引:97
|
作者
SPEER, CP
GEFELLER, O
GRONECK, P
LAUFKOTTER, E
ROLL, C
HANSSLER, L
HARMS, K
HERTING, E
BOENISCH, H
WINDELER, J
ROBERTSON, B
机构
[1] UNIV GOTTINGEN, DEPT PAEDIAT, GOTTINGEN, GERMANY
[2] STADT KRANKENHAUS COLOGNE, DEPT MED STAT, COLOGNE, GERMANY
[3] STADT KRANKENHAUS COLOGNE, DEPT PAEDIAT, COLOGNE, GERMANY
[4] RUHR UNIV BOCHUM, DEPT PAEDIAT, BOCHUM, GERMANY
[5] UNIV ESSEN GESAMTHSCH, DEPT PAEDIAT, ESSEN, GERMANY
[6] STADT KRANKENHAUS BRAUNSCHWEIG, BRAUNSCHWEIG, GERMANY
[7] RUHR UNIV BOCHUM, DEPT MED INFORMAT & BIOMATH, BOCHUM, GERMANY
[8] KAROLINSKA INST, KAROLINSKA HOSP, RES UNIT EXPTL PERINATAL PATHOL, S-10401 STOCKHOLM, SWEDEN
来源
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION | 1995年 / 72卷 / 01期
关键词
SURFACTANT TREATMENT; RESPIRATORY DISTRESS SYNDROME; CUROSURF; SURVANTA;
D O I
10.1136/fn.72.1.F8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aims-To compare treatment regimens of two widely used natural surfactant preparations Curosurf and Survanta in respiratory distress syndrome (RDS). Methods-The effects of the two treatment regimens on gas exchange, ventilatory requirements, and 28 day outcome in infants with RDS were compared. Seventy fire preterm infants (birth weight 700-1500 g) with RDS requiring artificial ventilation with an FIO2 of greater than or equal to 0.4, were randomly selected at 1-24 hours of age. One group received an initial dose of Curosurf (200 mg/kg); the other group Survanta (100 mg/kg). Patients who remained dependent on artificial ventilation with an FIO2 of greater than or equal to 0.3 received up to two additional doses of Curosurf (each of 100 mg/kg) after 12 and 24 hours or up to three additional doses of Survanta (each of 100 mg/kg) between six and 48 hours after the initial dose. Results-There was a rapid improvement in oxygenation and ventilatory requirements were reduced in both groups. However, infants treated with Curosurf had a higher arterial:alveolar oxygen tension ratio and required a lower peak inspiratory pressure and mean airway pressure at several time points within 24 hours of randomisation (p<0.05-0.001). The incidences of pneumothorax in the Curosurf and Survanta groups were 6% and 12.5%, respectively; the corresponding figures for grades 3-4 intracerebral haemorrhage were 3% and 12.5%, respectively. Mortality was 3% in the Curosurf group and 12.5% in the Survanta group. However, these differences did not reach significance. Conclusion-The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours aft er start of treatment. This was associated with a trend towards reduced incidence of serious pulmonary and nonpulmonary complications.
引用
收藏
页码:F8 / F13
页数:6
相关论文
共 50 条
  • [1] Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome
    Baroutis, G
    Kaleyias, J
    Liarou, T
    Papathoma, E
    Hatzistamatiou, Z
    Costalos, C
    EUROPEAN JOURNAL OF PEDIATRICS, 2003, 162 (7-8) : 476 - 480
  • [2] Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome
    Georgios Baroutis
    Joseph Kaleyias
    Theodora Liarou
    Eugenia Papathoma
    Zoe Hatzistamatiou
    Christos Costalos
    European Journal of Pediatrics, 2003, 162 : 476 - 480
  • [3] COMPARISON OF 2 BOVINE SURFACTANT PREPARATIONS IN THE TREATMENT OF RESPIRATORY-DISTRESS-SYNDROME IN PREMATURES
    SCHARF, J
    KLINGE, J
    BOSWALD, M
    DISTEL, D
    WILD, F
    TENBRINK, U
    HARMS, D
    MONATSSCHRIFT KINDERHEILKUNDE, 1994, 142 (12) : 961 - 966
  • [4] RANDOMIZED MULTICENTER TRIAL OF TREATMENT WITH PORCINE NATURAL SURFACTANT FOR MODERATELY SEVERE NEONATAL RESPIRATORY-DISTRESS SYNDROME
    BEVILACQUA, G
    HALLIDAY, H
    PARMIGIANI, S
    ROBERTSON, B
    JOURNAL OF PERINATAL MEDICINE, 1993, 21 (05) : 329 - 340
  • [5] A MULTICENTER RANDOMIZED CONTROLLED CLINICAL-TRIAL OF BOVINE SURFACTANT FOR PREVENTION OF RESPIRATORY-DISTRESS SYNDROME
    GORTNER, L
    BERNSAU, U
    HELLWEGE, HH
    HIERONIMI, G
    JORCH, G
    REITER, HL
    LUNG, 1990, 168 : 864 - 869
  • [6] A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome
    Arnold, C
    Adams, E
    Vollman, J
    Giebner, D
    Maurer, M
    Dreyer, G
    Bailey, L
    Anderson, M
    Mefford, L
    Beaumont, E
    Sutton, D
    Puppala, B
    Mangurten, HH
    Secrest, J
    Lewis, WJ
    Carteaux, P
    Bednarek, F
    Welsberger, S
    Gosselin, R
    Pantoja, AF
    Belenky, A
    Campbell, P
    Patole, S
    Duenas, M
    Kelly, M
    Alejo, W
    Lewallen, P
    DeanLieber, S
    Hanft, M
    Ferlauto, J
    Newell, RW
    Bagwell, J
    Levine, D
    Lipp, RW
    Harkavy, K
    Vasa, R
    Birenbaum, H
    Broderick, KA
    Santos, AQ
    Long, BA
    Gulrajani, M
    Stern, M
    Hopgood, G
    Hegyi, T
    Alba, J
    Christmas, L
    McQueen, M
    Nichols, N
    Brown, M
    Quissell, BJ
    PEDIATRICS, 1996, 97 (01) : 1 - 6
  • [7] A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome
    Malloy, CA
    Nicoski, P
    Muraskas, JK
    ACTA PAEDIATRICA, 2005, 94 (06) : 779 - 784
  • [8] Surfactant for respiratory distress syndrome: are there important clinical differences among preparations?
    Sinha, Sunil
    Moya, Fernando
    Donn, Steven M.
    CURRENT OPINION IN PEDIATRICS, 2007, 19 (02) : 150 - 154
  • [9] Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial
    Najafian, Bita
    Karimi-Sari, Hamidreza
    Khosravi, Mohammad Hossein
    Nikjoo, Niloofar
    Amin, Sobhan
    Shohrati, Majid
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2016, 3 : 55 - 59
  • [10] Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome
    Lam, BCC
    Ng, YK
    Wong, KY
    PEDIATRIC PULMONOLOGY, 2005, 39 (01) : 64 - 69